The heterogeneity of HER2-low breast cancer is evident, and previous studies have attempted to characterize and classify it by molecular characteristics of primary tumor tissues.21,41–43 Due to the spatial and temporal heterogeneity of HER2, relying solely on primary tissue may not accurately reflect the molecular characteristics of MBC patients. This evidence concerns the gene ERBB2 and neoplasm.